Angle plc: peers
Angle plc beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Angle plc, EKF Diagnostics Holdings plc, BioPorto A/S, Renalytix plc, Gentian Diagnostics AS, Burning Rock Biotech Limited: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Angle plcbase AGL.L · 🇬🇧 GB Percentile in Healthcare Percentile in UK | OneMedNet Corp ONMD · 🇬🇧 GB Percentile in Healthcare Percentile in UK | EKF Diagnostics Holdings plc EKF.L · 🇬🇧 GB Percentile in Healthcare Percentile in UK | BioPorto A/S BIOPOR.CO · 🇩🇰 DK Percentile in Healthcare Percentile in Denmark | Renalytix plc RNLXY · 🇬🇧 GB Percentile in Healthcare Percentile in UK | Gentian Diagnostics AS 6FK.F · 🇳🇴 NO Percentile in Healthcare Percentile in Norway | Insight Molecular Diagnostics Inc. IMDX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Burning Rock Biotech Limited BNR · 🇨🇳 CN Percentile in Healthcare Percentile in China | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $104 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8 | $237 MOct 14, 2026 · Market data1st of 8 | $182 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8 | $118 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $21 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8 | $71 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one7th of 8 | $98 MOct 27, 2026 · Market data5th of 8 | $93 MAug 1, 2026 · Market data6th of 8 | $101 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $1 MFY2025 · SEC5th of 5 | —— | —— | $2 MFY2024 · SEC4th of 5 | $17 MFY2025 · ESEF2nd of 5 | $4 MFY2025 · SEC3rd of 5 | $77 MFY2025 · SEC1st of 5 | $4 M5 ranked |
| Net income (Higher is better) | —— | $-3 MFY2025 · SEC2nd of 5 | —— | —— | $-33 MFY2024 · SEC4th of 5 | $1 MFY2025 · ESEF1st of 5 | $-50 MFY2025 · SEC5th of 5 | $-8 MFY2025 · SEC3rd of 5 | $-8 M5 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | —— | 15as reported · Profile2nd of 2 | —— | —— | —— | 753As on 2020 · Profile1st of 2 | 3842 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +112.5%FY2025 · SEC2nd of 592nd99th | ———— | ———— | -32.6%FY2024 · SEC5th of 57th1st | +20.0%FY2025 · ESEF3rd of 569th77th | +116.0%FY2025 · SEC1st of 593rd97th | +9.2%FY2025 · SEC4th of 548th55th | +20.0%5 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | +5.8%FY2025 · SEC3rd of 444th51st | ———— | ———— | +15.4%FY2024 · SEC2nd of 465th80th | ———— | +61.7%FY2025 · SEC1st of 492nd97th | -1.9%FY2025 · SEC4th of 422nd47th | +10.6%4 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | -69.0%FY2025 · ESEFonly one with it4th6th | ———— | ———— | -69.0%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | -36.8%FY2025 · SEC5th of 51st1st | ———— | ———— | 7.0%FY2024 · SEC4th of 54th5th | 55.6%FY2025 · ESEF3rd of 545th79th | 56.6%FY2025 · SEC2nd of 548th70th | 74.7%FY2025 · SEC1st of 574th95th | 55.6%5 ranked |
| Operating margin (Higher is better) | ———— | -711.0%FY2025 · SEC3rd of 33rd0th | ———— | ———— | ———— | 14.4%FY2025 · ESEF1st of 381st73rd | ———— | -10.2%FY2025 · SEC2nd of 348th43rd | -10.2%3 ranked |
| Net margin (Higher is better) | ———— | -205.9%FY2025 · SEC3rd of 315th2nd | ———— | ———— | ———— | 7.5%FY2025 · ESEF1st of 375th68th | ———— | -10.3%FY2025 · SEC2nd of 347th41st | -10.3%3 ranked |
| Free cash flow margin (Higher is better) | ———— | -552.2%FY2025 · SEC3rd of 46th1st | ———— | ———— | ———— | 23.4%FY2025 · ESEF1st of 492nd88th | -624.6%FY2025 · SEC4th of 44th1st | -6.3%FY2025 · SEC2nd of 444th39th | -279.2%4 ranked |
| Return on equity (Higher is better) | ———— | ———— | ———— | ———— | ———— | 6.8%FY2025 · ESEF1st of 277th45th | ———— | -10.2%FY2025 · SEC2nd of 266th40th | -1.7%2 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | 163.6×price Oct 14, 2026 · Market data1st of 296th97th | ———— | ———— | ———— | ———— | 24.2×price Oct 27, 2026 · Market data2nd of 285th95th | 1.2׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 93.9×2 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 1.2׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | —— |
| Free cash flow yield (Higher is better) | ———— | -3.2%price Oct 14, 2026 · Market data1st of 258th32nd | ———— | ———— | ———— | ———— | -25.8%price Oct 27, 2026 · Market data2nd of 228th13th | -5.2%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | -14.5%2 ranked |
| Financial strength | |||||||||
| Interest cover (Higher is better) | ———— | -138.1×FY2025 · SEConly one with it11th3rd | ———— | ———— | ———— | ———— | ———— | ———— | -138.1×— |
| Piotroski F-score (Higher is better) | —— | 5 of 9FY2025 · SEConly one with it | —— | —— | —— | —— | —— | —— | 5.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 4 of 19FY2025 · Scorecard5th of 5 | —— | —— | 3 of 10FY2024 · Scorecard3rd of 5 | 3 of 5FY2025 · Scorecard1st of 5 | 5 of 17FY2025 · Scorecard4th of 5 | 4 of 13FY2025 · Scorecard2nd of 5 | 30% passed5 ranked |
| Valuation checks (Higher is better) | —— | 0 of 5FY2025 · Scorecard1st of 2 | —— | —— | —— | —— | 0 of 5FY2025 · Scorecard1st of 2 | —— | 0% passed2 ranked |
| Growth checks (Higher is better) | —— | 3 of 4FY2025 · Scorecard1st of 5 | —— | —— | 3 of 5FY2024 · Scorecard3rd of 5 | 1 of 2FY2025 · Scorecard4th of 5 | 4 of 6FY2025 · Scorecard2nd of 5 | 2 of 5FY2025 · Scorecard5th of 5 | 60% passed5 ranked |
| Profitability checks (Higher is better) | —— | 0 of 4FY2025 · Scorecard3rd of 5 | —— | —— | 0 of 2FY2024 · Scorecard3rd of 5 | 2 of 3FY2025 · Scorecard1st of 5 | 0 of 2FY2025 · Scorecard3rd of 5 | 1 of 5FY2025 · Scorecard2nd of 5 | 0% passed5 ranked |
| Financial health checks (Higher is better) | —— | 1 of 5FY2025 · Scorecard3rd of 4 | —— | —— | 0 of 2FY2024 · Scorecard4th of 4 | —— | 1 of 3FY2025 · Scorecard1st of 4 | 1 of 3FY2025 · Scorecard1st of 4 | 27% passed4 ranked |
| Shareholder returns checks (Higher is better) | —— | 0 of 1FY2025 · Scorecard1st of 3 | —— | —— | 0 of 1FY2024 · Scorecard1st of 3 | —— | 0 of 1FY2025 · Scorecard1st of 3 | —— | 0% passed3 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 2.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | —— | —— | 56.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | —— | 29.7%2 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2 | —— | —— | —— | —— | 442026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2 | —— | 292 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | —— | —— | -2.5 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | —— | -2.5 pp— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Angle plc: How market caps are worked out; OneMedNet Corp: How market caps are worked out; EKF Diagnostics Holdings plc: How market caps are worked out; BioPorto A/S: How market caps are worked out; Renalytix plc: How market caps are worked out; Gentian Diagnostics AS: How market caps are worked out; Insight Molecular Diagnostics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Burning Rock Biotech Limited: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Angle plc | — | — | — |
| OneMedNet Corp | -711.0%FY2025 | 3rd percentile in Healthcaremedian -7.7%, 674 companies | 0th percentile in UKmedian 8.5%, 313 companies |
| EKF Diagnostics Holdings plc | — | — | — |
| BioPorto A/S | — | — | — |
| Renalytix plc | — | — | — |
| Gentian Diagnostics AS | 14.4%FY2025 | 81st percentile in Healthcaremedian -7.7%, 674 companies | 73rd percentile in Norwaymedian 6.0%, 95 companies |
| Insight Molecular Diagnostics Inc. | — | — | — |
| Burning Rock Biotech Limited | -10.2%FY2025 | 48th percentile in Healthcaremedian -7.7%, 674 companies | 43rd percentile in Chinamedian -5.9%, 135 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Angle plc | OneMedNet Corp | EKF Diagnostics Holdings plc | BioPorto A/S | Renalytix plc | Gentian Diagnostics AS | Insight Molecular Diagnostics Inc. | Burning Rock Biotech Limited |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | $1 MSEC4th | — | — | — | $17 MESEF2nd | $4 MSEC3rd | $77 MSEC1st |
| 2024 | — | $1 MSEC5th | — | — | $2 MSEC3rd | $14 MESEF2nd | $2 MSEC4th | $71 MSEC1st |
| 2023 | — | $1 MSEC4th | — | — | $3 MSEC2nd | — | $2 MSEC3rd | $76 MSEC1st |
| 2022 | — | $1 MSEC3rd | — | — | $3 MSEC2nd | — | $1 MSEC4th | $82 MSEC1st |
| 2021 | — | — | — | — | $1 MSEC3rd | — | $2 MSEC2nd | $80 MSEC1st |
| 2020 | — | — | — | — | — | — | $1 MSEC2nd | $66 MSEC1st |
| 2018 | — | — | — | — | — | — | — | $32 MSEC |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Angle plc#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- OneMedNet CorpONMD · 🇬🇧 UKSame industry: Diagnostics and Research · Similar size: $237 M market cap against $104 M · Same country: UK · Ratios of the last two fiscal years on fileMarket cap $237 M (Oct 14, 2026) · revenue $1 M (year to December 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)In the group
- EKF Diagnostics Holdings plcEKF.L · 🇬🇧 UKSame industry: Diagnostics and Research · Similar size: $182 M market cap against $104 M · Same country: UKMarket cap $182 M (last known, Jan 5, 2024)91 of 100 (industry or sector 50 + size 26 + country 15)In the group
- BioPorto A/SBIOPOR.CO · 🇩🇰 DenmarkSame industry: Diagnostics and Research · Similar size: $118 M market cap against $104 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $118 M (last known, Jan 5, 2024)91 of 100 (industry or sector 50 + size 29 + country 7 + figures on file 5)In the group
- Renalytix plcRNLXY · 🇬🇧 UKSame industry: Diagnostics and Research · Similar size: $21 M market cap against $104 M · Same country: UK · Ratios of the last two fiscal years on fileMarket cap $21 M (last known, Jan 5, 2024) · revenue $2 M (year to June 2024)90 of 100 (industry or sector 50 + size 20 + country 15 + figures on file 5)In the group
- Gentian Diagnostics AS6FK.F · 🇳🇴 NorwaySame industry: Diagnostics and Research · Similar size: $71 M market cap against $104 M · Same region: Northern Europe · Ratios of the last two fiscal years on fileMarket cap $71 M (last known, Jul 30, 2023) · revenue $17 M (year to December 2025)90 of 100 (industry or sector 50 + size 28 + country 7 + figures on file 5)In the group
- Insight Molecular Diagnostics Inc.IMDX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $98 M market cap against $104 M · Ratios of the last two fiscal years on fileMarket cap $98 M (Oct 27, 2026) · revenue $4 M (year to December 2025)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Burning Rock Biotech LimitedBNR · 🇨🇳 ChinaSame industry: Diagnostics and Research · Similar size: $93 M market cap against $104 M · Ratios of the last two fiscal years on fileMarket cap $93 M (Aug 1, 2026) · revenue $77 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Yourgene Health PLCYGEN.L · 🇬🇧 UKSame industry: Diagnostics and Research · 5.2× smaller by market cap · Same country: UKMarket cap $20 M (last known, Jul 30, 2023)84 of 100 (industry or sector 50 + size 19 + country 15)+ Add
- Anixa Biosciences, Inc.ANIX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $117 M market cap against $104 M · Ratios of the last two fiscal years on fileMarket cap $117 M (Oct 29, 2026)84 of 100 (industry or sector 50 + size 29 + figures on file 5)+ Add
- Sera Prognostics, Inc.SERA · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $82 M market cap against $104 M · Ratios of the last two fiscal years on fileMarket cap $82 M (Oct 30, 2026) · revenue $0 M (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Abingdon Health PlcABDX.L · 🇬🇧 UKSame industry: Diagnostics and Research · 6.1× smaller by market cap · Same country: UKMarket cap $17 M (last known, Jan 5, 2024)83 of 100 (industry or sector 50 + size 18 + country 15)+ Add
- MaxCyte, Inc.MXCT · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $156 M market cap against $104 M · Ratios of the last two fiscal years on fileMarket cap $156 M (Oct 27, 2026) · revenue $33 M (year to December 2025)82 of 100 (industry or sector 50 + size 27 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.